Weekly Pharmaceutical Industry Research Report: Illumina's Billion Cell Atlas Unveils Causal Mechanisms of Life; Regulatory Tailwinds Accelerate Innovation, CXO Sector Remains Strong

Core Points

Industry Frontier

(1) Frontier Trends: Illumina Releases the Billion Cell Atlas, the first achievement in its plan to construct a five billion cell atlas within three years, which will become the most comprehensive biological map of human diseases to date; life data enters a new AI era. We believe this will advance the development of life science data infrastructure and usher in a new phase where biology intersects with AI. There are three key points: ① Transformation of Data Access Leaders: Shifting from sequencing hardware to efficient AI data providers; ② New AI Ecosystem: Cross-industry leaders teaming up to build disruptive new life science data; ③ A Computable New Era for Life Sciences: Data infrastructure transformation propelling a new AI-driven pharmaceutical era—just as primitive humans evolved from blindly navigating rugged terrains by sight alone to effectively advancing with satellite navigation, the solving of difficult human diseases will enter an AI-driven new era. (2) Regulatory Trends: China implements eCTD, while the U.S. supports Bayesian methods, intensifying the race in speed. (3) The global order recovery momentum is clear, with a positive outlook for the CXO track throughout 2026.

Capital Trends

(1) GSK bets on IgE for anti-food allergy, acquiring RAPT Therapeutics for $2.2 billion. Notably, according to PharmaCube reports, LongBio's core product LP-003, which is soon to be listed on the Hong Kong stock exchange, is the fastest-progressing next-generation IgE monoclonal antibody globally and has outperformed omalizumab in a head-to-head phase II clinical trial for chronic urticaria. (2) Novartis advances in Alzheimer’s, acquiring SciNeuro's Aβ protein bispecific antibody for $1.5 billion.

This Week's Perspective

In summary, we believe that from the deciphering of the static human genome map in the 1990s to Illumina's release today of a dataset based on the causal correspondence between individual gene survival and cellular operational changes, global pharmaceuticals and healthcare have entered a new era of AI-driven computable reasoning. Driven by advancements in technology and regulatory progress, the previous rapid advantage in research and development will be "inflated," and the time-based leading barrier may become fragile under the current new ecosystem. Meanwhile, as AI-driven or AI-empowered drug discovery soars, demand in the CXO sector will remain strong.